233 related articles for article (PubMed ID: 8042821)
21. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up.
Tune BM; Kirpekar R; Sibley RK; Reznik VM; Griswold WR; Mendoza SA
Clin Nephrol; 1995 Feb; 43(2):84-8. PubMed ID: 7736683
[TBL] [Abstract][Full Text] [Related]
22. Effective treatment administration of cyclophosphamide in membranous nephropathy.
Dede F; Ayili D; Sahiner S
J Nephrol; 2008; 21(4):560-5. PubMed ID: 18651546
[TBL] [Abstract][Full Text] [Related]
23. Idiopathic membranous nephropathy in the elderly.
Passerini P; Como G; Viganò E; Melis P; Pozzi C; Altieri P; Ponticelli C
Nephrol Dial Transplant; 1993; 8(12):1321-5. PubMed ID: 8159299
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide.
Flynn JT; Smoyer WE; Bunchman TE; Kershaw DB; Sedman AB
Am J Nephrol; 2001; 21(2):128-33. PubMed ID: 11359020
[TBL] [Abstract][Full Text] [Related]
25. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.
Torres A; Domínguez-Gil B; Carreño A; Hernández E; Morales E; Segura J; González E; Praga M
Kidney Int; 2002 Jan; 61(1):219-27. PubMed ID: 11786104
[TBL] [Abstract][Full Text] [Related]
26. Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis.
Brunkhorst R; Wrenger E; Koch KM
Clin Investig; 1994 Mar; 72(4):277-82. PubMed ID: 8043974
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
28. Cyclophosphamide or chlorambucil therapy is indicated in idiopathic membranous nephropathy with strong risk factors for progression.
Hebert LA; Rovin BH; Agarwal AK; Spetie DN
Am J Kidney Dis; 2005 Apr; 45(4):788-9; author replyy 789-90. PubMed ID: 15806488
[No Abstract] [Full Text] [Related]
29. Idiopathic Membranous Nephropathy and Treatment Related Complications.
Uncanin S; Dzemidzic J; Serdarevic N; Muslimovic A; Haskovic D
Med Arch; 2020 Jun; 74(3):228-232. PubMed ID: 32801441
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide.
Branten AJ; du Buf-Vereijken PW; Vervloet M; Wetzels JF
Am J Kidney Dis; 2007 Aug; 50(2):248-56. PubMed ID: 17660026
[TBL] [Abstract][Full Text] [Related]
31. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.
Ponticelli C; Zucchelli P; Passerini P; Cesana B; Locatelli F; Pasquali S; Sasdelli M; Redaelli B; Grassi C; Pozzi C
Kidney Int; 1995 Nov; 48(5):1600-4. PubMed ID: 8544420
[TBL] [Abstract][Full Text] [Related]
32. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function.
Jindal K; West M; Bear R; Goldstein M
Am J Kidney Dis; 1992 Jan; 19(1):61-7. PubMed ID: 1739084
[TBL] [Abstract][Full Text] [Related]
33. Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy.
Naumovic R; Furuncic D; Jovanovic D; Stosovic M; Basta-Jovanovic G; Lezaic V
Biomed Pharmacother; 2010 Nov; 64(9):633-8. PubMed ID: 20888177
[TBL] [Abstract][Full Text] [Related]
34. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide.
Tumlin JA; Lohavichan V; Hennigar R
Nephrol Dial Transplant; 2003 Jul; 18(7):1321-9. PubMed ID: 12808169
[TBL] [Abstract][Full Text] [Related]
35. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide.
Levey AS; Lan SP; Corwin HL; Kasinath BS; Lachin J; Neilson EG; Hunsicker LG; Lewis EJ
Ann Intern Med; 1992 Jan; 116(2):114-23. PubMed ID: 1727614
[TBL] [Abstract][Full Text] [Related]
36. [Cyclophosphamide pulse therapy in patients with primary glomerulonephritis].
Rutkowski B; Wielgosz A; Manitius J; Bułło B; Kowalewska J; Tylicki L; Roszkiewicz A
Przegl Lek; 2000; 57(11):624-7. PubMed ID: 11293209
[TBL] [Abstract][Full Text] [Related]
37. Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults.
Ponticelli C; Passerini P
Clin Nephrol; 1991; 35 Suppl 1():S16-21. PubMed ID: 1860261
[TBL] [Abstract][Full Text] [Related]
38. Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents.
Griswold WR; Tune BM; Reznik VM; Vazquez M; Prime DJ; Brock P; Mendoza SA
Nephron; 1987; 46(1):73-7. PubMed ID: 3600915
[TBL] [Abstract][Full Text] [Related]
39. [Appraisal of renal failure reversing therapies in lupus nephritis].
Yang X; Liang L; Zhan Z; Ye Y; Liu Y; Yu X; Chen W; Yin P
Zhonghua Nei Ke Za Zhi; 2001 Feb; 40(2):113-6. PubMed ID: 11798566
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of low-dose glucocorticoid regimen in association with cyclophosphamide in patients with glomerulonephritis.
Hirja AR; Voroneanu L; Siriopol D; Nistor I; Hogas S; Apetrii M; Volovat C; Veisa G; Mititiuc IL; Florea L; Onofriescu M; Covic A
Int Urol Nephrol; 2019 Oct; 51(10):1805-1813. PubMed ID: 31385176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
